By Jeff Bader -Posted October 13, 2018 02:08:20Neurology of those who are dead may have been more complicated than the brain-dead of the living.
It was a topic that had to be tackled in an effort to help those who had been stricken with dementia, or even asymptomatic dementia, as it was called.
It wasn’t an easy task.
Many people in the 1920s and 1930s were dying from other causes as well as from diseases like tuberculosis, typhoid, and malaria, which also made it a difficult subject to study.
But as neurosurgeons and medical educators in the 1940s and 1950s developed methods to better treat the conditions they were treating, more and more people with dementia were able to be treated in hospitals and clinics.
Neurosurgeons at the University of Chicago in the early 1950s were experimenting with a technique called electroshock therapy, which was supposed to increase the brain’s blood flow, and were finding that it reduced the frequency of seizures and other brain symptoms in people with the disease.
This allowed them to diagnose and treat patients who had the disorder.
But because the procedure was often painful, and it didn’t always improve symptoms, some patients were dying of complications of the treatment.
Eventually, in the 1970s, researchers at Yale University began to study the effects of electroshock treatment on people who were dead, and found that people with brain disease had more brain damage.
They found that the higher a person’s blood pressure, the more severe and disabling the brain disorder was.
As a result, neurologists at the Yale Medical School in the mid-1980s started using electroshock as a treatment for dementia.
They started using the technique on a patient who had cerebral palsy, which made it possible to control seizures and improve symptoms.
In the 1990s, however, neurology began to shift from using electroconvulsive therapy (ECT) as a means of controlling seizures to using it to treat people with Alzheimer’s disease.
But some people with mild to moderate Alzheimer’s were still suffering from severe neurological problems.
In 2008, the American Society of Neurology’s board of directors approved the use of a new form of the therapy called transcranial magnetic stimulation (TMS), which was similar to the therapy used in the 1950s and 1960s, but without the electrodes attached to the patient’s brain.
The procedure involves a magnetic field that passes through the skin, causing the brain to stimulate nerve cells in the brain.TMS can reduce seizures, increase brain activity, and reduce symptoms of the disease, but it also can cause some side effects that can interfere with care.
So in the last five years, more than 100,000 people have received TMS treatment.
Most of the time, people with cerebral palsys have mild to mild symptoms of Alzheimer’s, and some of the symptoms are milder than what people with a milder form of Alzheimer would have.
But there are some people who don’t respond well to TMS and others who have mild or severe symptoms.
For these people, TMS has been shown to be effective in treating symptoms, but the procedure can also cause side effects.
In 2012, researchers from Duke University in North Carolina tested the effectiveness of TMS on a group of people who had mild to severe symptoms of mild to moderately severe Alzheimer’s.
They wanted to see if TMS could prevent the onset of dementia.
So the researchers enrolled 20 people who lived in an apartment complex in Durham, North Carolina, and took them to the hospital for an assessment.
The people were followed for 12 weeks, and the researchers measured the patients’ brain waves during the assessments.
They also sent the participants brain waves back to the complex to see how the changes in brain activity were related to the changes on the EEG.
After the first two weeks, there were fewer changes on a brain wave index, or EEG, than when the patients were receiving the TMS.
But the changes were still there.
Then, after the third week, the EEG was no longer correlated with the changes.
In other words, the patients had shown signs of dementia, but they were showing no signs of Alzheimer.
“At that point, we thought, we need to find out what’s causing the changes,” says neurosurgeon Paul Toth, who was one of the researchers.
Toth was not involved in the study.
But he says the findings were significant because it suggests that TMS might not be as effective as we thought.
The study is not yet peer-reviewed, so it was not immediately clear how much the findings will help people who are living with Alzheimer and don’t have the disease themselves.
But Toth says the data does raise a few questions: What can be done to prevent the progression of dementia and to reduce the risk of dementia?
And how much TMS should be used?
“I think there is an important opportunity for a clinical trial